Tracer Biotechnologies Collaborates with AstraZeneca for Cancer Monitoring
Tracer Biotechnologies, a pioneering company in next-generation diagnostics, has entered into an exciting multi-year collaboration with AstraZeneca, a global leader in biopharmaceuticals. This partnership marks a significant milestone in advancing innovative diagnostic technologies aimed at improving cancer patient monitoring during drug development.
Enhancing Clinical Trials with ctDNA Testing
The core of this agreement allows AstraZeneca to utilize Tracer's cutting-edge circulating tumor DNA (ctDNA) monitoring technology throughout its clinical trials. Tracer has established a proprietary platform that employs digital polymerase chain reaction (PCR) for tumor-informed ctDNA detection. This innovative approach ensures optimized ctDNA detection, making it a cost-effective, precise, and scalable option for patient testing, serving as a valuable alternative to traditional radiographic imaging methods.
Transforming Cancer Treatment Monitoring
Mark Kaganovich, the CEO of Tracer Biotechnologies, emphasized, "We are entering a new era of oncology where patients will no longer have to rely on expensive and imprecise radiographic scans to evaluate treatment efficacy and track disease progression." This statement underlines the transformative potential of the collaboration, which aims to provide frequent, accurate, and economical ctDNA measurements for detecting minimal residual disease and monitoring treatment responses.
About Tracer Biotechnologies
Founded with a goal to revolutionize cancer diagnostics, Tracer Biotechnologies stands out as a next-generation diagnostics company. It offers the only ultrasensitive ctDNA assay designed for Molecular Response surveillance. Through the synergy of tumor-informed personalization and digital PCR, Tracer provides cost-effective assays capable of accommodating an unlimited number of timepoints in clinical studies. Their ctDNA assays are available for both blood and urine testing, reflecting a comprehensive approach to cancer monitoring.
Future Directions for Cancer Diagnostics
The collaboration with AstraZeneca not only showcases Tracer's innovations but also highlights the growing importance of personalizing cancer treatment. By leveraging technology that provides real-time insights into a patient's cancer status, oncologists can make more informed decisions regarding treatment options, thereby enhancing patient outcomes.
Frequently Asked Questions
What is the main purpose of the Tracer and AstraZeneca collaboration?
The collaboration aims to utilize Tracer’s ctDNA monitoring technology to enhance cancer patient monitoring in clinical trials, offering a more precise alternative to traditional imaging methods.
How does Tracer's ctDNA monitoring technology work?
Tracer's technology utilizes digital PCR to perform tumor-informed ctDNA detection, which allows for cost-effective and precise testing of patients, improving the monitoring of treatment responses.
Who is the CEO of Tracer Biotechnologies?
Mark Kaganovich serves as the CEO of Tracer Biotechnologies, driving the company’s vision for innovative cancer diagnostics.
What types of samples does Tracer’s assays analyze?
Tracer’s assays are designed to analyze ctDNA from both blood and urine samples, providing a more flexible approach to cancer diagnostics.
Why is this collaboration significant for oncology?
This collaboration is significant because it represents a shift towards more personalized and real-time cancer treatment monitoring, which can lead to better patient outcomes and more tailored oncology therapies.
